Research programme: small activating RNA therapeutics - MiNA Therapeutics

Drug Profile

Research programme: small activating RNA therapeutics - MiNA Therapeutics

Alternative Names: RNAa - Mina Therapeutics; saRNA - MiNA Therapeutics

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MiNA Therapeutics; University of California at San Francisco; University of Texas Southwestern Medical Center
  • Developer Marina Biotech; MiNA Therapeutics
  • Class RNA
  • Mechanism of Action RNA stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Liver cancer

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Liver-cancer in United Kingdom (Parenteral)
  • 03 Nov 2015 Marina Biotech has patent protection for SMARTICLES® delivery technology and for the composition of NOV 340 in Canada
  • 01 Dec 2014 MiNA Therapeutics receives patent allowance for saRNA therapeutics in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top